ATE234920T1 - Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen - Google Patents

Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen

Info

Publication number
ATE234920T1
ATE234920T1 AT93924777T AT93924777T ATE234920T1 AT E234920 T1 ATE234920 T1 AT E234920T1 AT 93924777 T AT93924777 T AT 93924777T AT 93924777 T AT93924777 T AT 93924777T AT E234920 T1 ATE234920 T1 AT E234920T1
Authority
AT
Austria
Prior art keywords
kinases
serine
kinase domain
threonine kinase
proteins
Prior art date
Application number
AT93924777T
Other languages
English (en)
Inventor
Kohei Miyazono
Peter Ten Dijke
Petra Franzen
Hidetoshi Yamashita
Carl-Henrik Heldin
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224057A external-priority patent/GB9224057D0/en
Priority claimed from GB939304680A external-priority patent/GB9304680D0/en
Priority claimed from GB939304677A external-priority patent/GB9304677D0/en
Priority claimed from GB939311047A external-priority patent/GB9311047D0/en
Priority claimed from GB939313763A external-priority patent/GB9313763D0/en
Priority claimed from GB939316099A external-priority patent/GB9316099D0/en
Priority claimed from GB939321344A external-priority patent/GB9321344D0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE234920T1 publication Critical patent/ATE234920T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT93924777T 1992-11-17 1993-11-17 Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen ATE234920T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB929224057A GB9224057D0 (en) 1992-11-17 1992-11-17 Novel protein kinase receptors
GB939304680A GB9304680D0 (en) 1993-03-08 1993-03-08 Protein kinases
GB939304677A GB9304677D0 (en) 1993-03-08 1993-03-08 Protein kinases
GB939311047A GB9311047D0 (en) 1993-05-28 1993-05-28 Protein kinases
GB939313763A GB9313763D0 (en) 1993-07-02 1993-07-02 Protein kinases
GB939316099A GB9316099D0 (en) 1993-08-03 1993-08-03 Protein kinases
GB939321344A GB9321344D0 (en) 1993-10-15 1993-10-15 Protein kinases
PCT/GB1993/002367 WO1994011502A2 (en) 1992-11-17 1993-11-17 Activin receptor-like kinases, proteins having serine threonine kinase domains and their use

Publications (1)

Publication Number Publication Date
ATE234920T1 true ATE234920T1 (de) 2003-04-15

Family

ID=27562887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93924777T ATE234920T1 (de) 1992-11-17 1993-11-17 Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen

Country Status (10)

Country Link
US (5) US6316217B1 (de)
EP (1) EP0677104B1 (de)
JP (1) JP3362151B2 (de)
KR (1) KR950704485A (de)
AT (1) ATE234920T1 (de)
AU (1) AU683431B2 (de)
CA (1) CA2149441C (de)
DE (1) DE69332779T2 (de)
NZ (1) NZ257631A (de)
WO (1) WO1994011502A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US5863738A (en) 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US5968752A (en) * 1995-08-14 1999-10-19 Creative Biomolecules, Inc. Method for identifying an OP-1 analog which binds an ALK-1 receptor
WO1998049276A1 (fr) * 1997-04-28 1998-11-05 Helix Research Institute Serine/threonine proteine kinase
AU3092899A (en) * 1998-03-13 1999-09-27 Ludwig Institute For Cancer Research Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
WO2002094084A2 (en) * 2001-05-21 2002-11-28 University Of Iowa Research Foundation Bmpr1a involvement in juvenile polyposis
DK1670511T3 (da) * 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
WO2005077403A1 (en) * 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
US8410246B2 (en) 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
PL2960253T3 (pl) 2005-09-07 2018-11-30 Amgen Fremont Inc. Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
SI2497780T1 (sl) 2005-09-20 2015-08-31 Thrasos Innovation, Inc. Spojine, povezane s TDF, in njihovi analogi
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
MX2009004718A (es) 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
KR20190128254A (ko) 2008-05-02 2019-11-15 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
ES2575695T3 (es) 2009-03-30 2016-06-30 Acceleron Pharma Inc. Antagonistas de BMP-ALK3 y sus usos para estimular el crecimiento óseo
WO2013166438A1 (en) 2012-05-04 2013-11-07 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use
WO2016164089A2 (en) 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN105738630A (zh) * 2016-02-16 2016-07-06 林兴 丝/苏氨酸激酶抑制蛋白在治疗免疫性肝纤维化药物中的应用
CN105617369A (zh) * 2016-02-17 2016-06-01 林兴 丝/苏氨酸激酶抑制蛋白在治疗化学性肝纤维化药物中的应用
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR102359707B1 (ko) 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
MA46472A (fr) 2016-10-05 2019-08-14 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MX2020005405A (es) 2017-11-24 2020-08-13 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
US20230302135A1 (en) * 2020-08-26 2023-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Hybrid allosteric receptor-engineered stem cells
WO2023019185A1 (en) * 2021-08-10 2023-02-16 Gentibio, Inc. Compositions and methods for engineering stable tregs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE85080T1 (de) * 1984-02-17 1993-02-15 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
CA2164623A1 (en) * 1993-06-07 1994-12-22 Robert Enrico Pacifici Hybrid receptor molecules
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US5863738A (en) * 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor

Also Published As

Publication number Publication date
DE69332779T2 (de) 2003-10-23
US6207814B1 (en) 2001-03-27
NZ257631A (en) 1996-03-26
KR950704485A (ko) 1995-11-20
EP0677104B1 (de) 2003-03-19
JPH08505049A (ja) 1996-06-04
CA2149441C (en) 2004-03-02
US6316217B1 (en) 2001-11-13
EP0677104A1 (de) 1995-10-18
US20020123139A1 (en) 2002-09-05
JP3362151B2 (ja) 2003-01-07
WO1994011502A3 (en) 1994-07-07
US6271365B1 (en) 2001-08-07
DE69332779D1 (de) 2003-04-24
US6331621B1 (en) 2001-12-18
CA2149441A1 (en) 1994-05-26
AU683431B2 (en) 1997-11-13
WO1994011502A2 (en) 1994-05-26
US6982319B2 (en) 2006-01-03
AU5432094A (en) 1994-06-08

Similar Documents

Publication Publication Date Title
ATE234920T1 (de) Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
CO4180381A1 (es) Derivados opticamente activos de 2-imidazolin-5-onas y 2- imidazolina-5-tionas fungicidas
BR9307646A (pt) Pirrolopirimidinas como antagonistas de crf
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
AR007857A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
BRPI0111222B8 (pt) derivados fosfonados de glicopeptídeo.
AR007855A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
FR2678615B1 (fr) Benzofuranne-2-ones thiomethylees, leur preparation et leur application comme stabilisants de matieres organiques.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
FI853923A0 (fi) Substiteurade propan -fosfonsyrafoereningar.
ES2124668B1 (es) "nuevosl-arilpirazoles con propiedades plaguicidas.
AU1557400A (en) Absorbent elements for hygiene articles
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
ATE108058T1 (de) Tragestruktur für büro- und schreibtische, einschliesslich solcher mit mehreren stützebenen.
GEP20074210B (en) Tropane derivatives as ccr5 modulators
SE9700606L (sv) Vätskegenomsläppligt höljesskikt till absorberande alster
DE59601878D1 (de) Verwendung von schwerflüchtigen pyrazolderivaten mit hydrophilen gruppen als nitrifikationsinhibitoren
SE9604553D0 (sv) Vätskemottagande skikt till absorberande alster
ATE244215T1 (de) Flüssigkristalline verbindungen
BR9607335A (pt) Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
YU78092A (sh) Postupak za dobijanje derivata beta-fenilizoserina i njihova primena
DE392909T1 (de) Elastische, hydraulisch gedaempfte buchse mit radialer elastizitaet und entkoppelung der steifigkeiten.
ES2171743T3 (es) Derivados de amidinas e isotioureas como inhibidores de la enzima sintasa de oxido nitrico.
ES2171697T3 (es) Antagonistas del receptor de endotelina.
NO913096L (no) Fremgangsmaate for fremstilling av formlegemer av silisiuminnfiltrert silisiumkarbid.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties